NCT03157674已完成不适用
Real-World Evidence and Treatment Patterns: Head and Neck Cancer
Bristol-Myers Squibb1 个研究点 分布在 1 个国家目标入组 43,994 人开始时间: 2016年11月24日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 43,994
- 试验地点
- 1
- 主要终点
- Proportion of patients receiving radiotherapy as anti-cancer treatment
研究概览
简要总结
This study will be focused on HNC patients who have been diagnosed with HNC between 01-Jan-2013 and 30-Sep-2016.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •HNC or undefined histology (not otherwise specified [NOS]) HNC diagnosis from 01-Jan-2013 to 30-Sep-2016 using Japanese disease code
- •Age 18 years or older at initial diagnosis of HNC regardless of staging
排除标准
- •Diagnosis of another malignancy on or before the initial diagnosis of HNC with the exception of non-melanoma skin cancer and metastatic cancer
- •Diagnosis of HNC before 01-Jan 2013 or after 30-Sep-2016
结局指标
主要结局
Proportion of patients receiving radiotherapy as anti-cancer treatment
时间窗: Approximately 45 months
Proportion of patients receiving supportive care as anti-cancer treatment
时间窗: Approximately 45 months
Proportion of patients receiving chemotherapy as anti-cancer treatment
时间窗: Approximately 45 months
Proportion of patients receiving surgery as anti-cancer treatment
时间窗: Approximately 45 months
Proportion of patients receiving targeted therapy as anti-cancer treatment
时间窗: Approximately 45 months
Distribution of Treatment History in Head and Neck Cancer (HNC) patients
时间窗: Approximately 45 months
次要结局
- Distribution of overall survival (OS) by stage(Approximately 45 months)
- Distribution of overall survival (OS) by treatment regimen(Approximately 45 months)
- Distribution of overall survival (OS) by age(Approximately 45 months)
- Number of withdrawals due to AEs(Approximately 45 months)
- Distribution of overall survival (OS) by gender(Approximately 45 months)
- Distribution of overall survival (OS) by tumor site(Approximately 45 months)
- Proportion of diagnosis of another malignancy on or before the initial diagnosis of HNC(At Baseline)
- Number of treatment-limiting adverse events (AEs)(Approximately 45 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Multicenter Registry Study of Chronic Hypoparathyroidism in Chinese AdultsChronic HypoparathyroidismNCT05214274Peking University524
Unknown
不适用
Registry for Pulmonary Hypertension in ChinaChronic Thromboembolic Pulmonary HypertensionPulmonary Arterial HypertensionDeathNCT01417338Chinese Academy of Medical Sciences, Fuwai Hospital3,079
已完成
不适用
The Nor-Hand StudyPainInflammationImage, BodyOsteoarthritisNCT03083548Diakonhjemmet Hospital300
进行中（未招募）
不适用
A Longitudinal Observational Study of the Natural History and Management of Patients With HCCHepatocellular CancerNCT02954094Target PharmaSolutions, Inc.10,000
已完成
2 期
Study of Cetuximab With Concomitant-boost Radiotherapy in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)Carcinoma of the Head and NeckNCT00865098Merck KGaA, Darmstadt, Germany27